Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,088.76

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,408.00 1
Travel and Lodging $1,179.11 6
Food and Beverage $501.65 7

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $7,838.76 12
Janssen Biotech, Inc. $250.00 2

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $8,088.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $6,408.0011/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917796 CMS
E.R. Squibb & Sons, L.L.C. $37.2411/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917789 CMS
E.R. Squibb & Sons, L.L.C. $132.0911/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917851 CMS
E.R. Squibb & Sons, L.L.C. $25.1911/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917859 CMS
E.R. Squibb & Sons, L.L.C. $20.5011/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917867 CMS
E.R. Squibb & Sons, L.L.C. $475.7411/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917875 CMS
E.R. Squibb & Sons, L.L.C. $108.9811/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917891 CMS
E.R. Squibb & Sons, L.L.C. $157.5511/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917899 CMS
E.R. Squibb & Sons, L.L.C. $199.0111/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917907 CMS
E.R. Squibb & Sons, L.L.C. $41.0411/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061065497 CMS
E.R. Squibb & Sons, L.L.C. $32.8311/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061065499 CMS
E.R. Squibb & Sons, L.L.C. $200.5911/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917883 CMS
Janssen Biotech, Inc. $125.0003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080723609 CMS
Janssen Biotech, Inc. $125.0003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080723611 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $181.44 12/29/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Random DB P3 Study in adult subjects with moderate to severe plaque psoriasis No dispute reported 06/30/2026 830986091
Principal investigator 1 Incyte Corporation $1,126.38 12/28/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132379
Principal investigator 1 Incyte Corporation $1,489.07 12/28/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132385
Principal investigator 1 Incyte Corporation $11,562.42 12/28/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132391
Principal investigator 1 Bausch Health US, LLC $5,358.19 12/22/2021 Non-covered Recipient Entity
Associated Skin Care Specialist PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850481441
Principal investigator 1 Incyte Corporation $8,125.00 12/17/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132373
Principal investigator 1 Incyte Corporation $6,978.52 12/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132363
Principal investigator 1 Incyte Corporation $7,198.63 12/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132369
Principal investigator 1 Incyte Corporation $4,068.61 11/24/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132357
Principal investigator 1 Bausch Health US, LLC $10,956.15 11/05/2021 Non-covered Recipient Entity
Associated Skin Care Specialist PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850481477
Principal investigator 1 ABBVIE INC. $7,153.90 11/04/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792481187
Principal investigator 1 Incyte Corporation $5,888.65 11/04/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132339
Principal investigator 1 Incyte Corporation $13,915.45 11/04/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132345
Principal investigator 1 Incyte Corporation $3,631.70 11/04/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132351
Principal investigator 1 Bausch Health US, LLC $3,500.00 10/29/2021 Non-covered Recipient Entity
Associated Skin Care Specialist PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850481515
Principal investigator 1 Incyte Corporation $5,000.00 10/27/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132333
Principal investigator 1 ABBVIE INC. $1,415.70 10/06/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792477479
Principal investigator 1 Incyte Corporation $6,271.09 10/06/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132315
Principal investigator 1 Incyte Corporation $4,000.38 10/06/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132321
Principal investigator 1 Incyte Corporation $7,847.53 10/06/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132327
Principal investigator 1 ABBVIE INC. $229.20 09/09/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792475013
Principal investigator 1 Incyte Corporation $8,923.66 09/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132298
Principal investigator 1 Incyte Corporation $14,223.96 09/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132303
Principal investigator 1 Incyte Corporation $1,664.43 09/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132309
Principal investigator 1 ABBVIE INC. $4,544.80 08/30/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792473073
Principal investigator 1 Incyte Corporation $6,655.32 08/05/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132281
Principal investigator 1 Incyte Corporation $4,423.00 08/05/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831132285
Principal investigator 1 Incyte Corporation $10,216.42 08/05/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132291
Principal investigator 1 Bausch Health US, LLC $3,000.00 07/30/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 850483445
Principal investigator 1 ABBVIE INC. $3,226.60 07/29/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792469203
Principal investigator 1 Incyte Corporation $9,001.44 06/30/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132251
Principal investigator 1 Amgen Inc. $98,122.93 06/24/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983033
Principal investigator 1 Incyte Corporation $13,573.98 06/03/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132239
Principal investigator 1 Incyte Corporation $4,423.00 06/03/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132245
Principal investigator 1 ABBVIE INC. $291.60 06/01/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792461491
Principal investigator 1 ABBVIE INC. $6,848.40 05/27/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792460067
Principal investigator 1 Eli Lilly and Company $15.00 05/10/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935508487
Principal investigator 1 Eli Lilly and Company $96.00 05/10/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935508713
Principal investigator 1 Eli Lilly and Company $50.00 05/10/2021 Non-covered Recipient Entity
NECCR PRIMA CARE RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935508793
Principal investigator 1 Eli Lilly and Company $204.00 05/10/2021 Non-covered Recipient Entity
GEISINGER CLINIC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935508937
Principal investigator 1 Eli Lilly and Company $3.00 05/10/2021 Non-covered Recipient Entity
RAPID MEDICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935509081
Principal investigator 1 Eli Lilly and Company $288.00 05/10/2021 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935509351
Principal investigator 1 ABBVIE INC. $2,863.20 05/06/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792455127
Recipient E.R. Squibb & Sons, L.L.C. $2,287.35 05/04/2021 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819890445
Principal investigator 1 Incyte Corporation $11,977.18 04/30/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132269
Principal investigator 1 ABBVIE INC. $5,112.90 04/29/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792448093
Principal investigator 1 Amgen Inc. $422,879.83 04/14/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983031
Principal investigator 1 ABBVIE INC. $3,386.30 04/09/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792444139
Recipient E.R. Squibb & Sons, L.L.C. $27,167.92 04/06/2021 Covered Recipient Physician A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819890457
Principal investigator 1 ABBVIE INC. $1,810.90 03/30/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792436215
Principal investigator 1 Incyte Corporation $6,575.12 03/26/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132263
Principal investigator 1 Eli Lilly and Company $13,363.00 03/11/2021 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 935508421
Principal investigator 1 Eli Lilly and Company $9,634.00 03/11/2021 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 935508533
Principal investigator 1 Amgen Inc. $1,201.32 03/03/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983035
Principal investigator 1 ABBVIE INC. $14,736.80 03/02/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792427055
Principal investigator 1 Incyte Corporation $12,471.54 02/26/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132257
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,945.59 02/09/2021 Non-covered Recipient Entity
Associated Skin Care Specialists - Minnesota Clinical Study Center
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819891623
Principal investigator 1 Eli Lilly and Company $807.00 02/08/2021 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935509265
Principal investigator 1 ABBVIE INC. $160.00 02/04/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792420853
Principal investigator 1 Incyte Corporation $11,900.58 01/29/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831132275
Principal investigator 1 ABBVIE INC. $2,667.30 01/28/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792416017
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,922.80 01/27/2021 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA MINNESOTA CLINICAL STUDY CENTER
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 800621897
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,550.00 01/15/2021 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 800636853
Principal investigator 1 Eli Lilly and Company $39,849.00 01/05/2021 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 935508735